MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-14-2022
Tricida EPS Ratio 2011-2026 | TCDA
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Tricida
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.44 | -5.29 | -3.72 | -4.64 | -19.3 | -15.7 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -3.44 | -19.3 | -8.68 |
Quarterly EPS Ratio Tricida
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -0.44 | -0.49 | -0.51 | - | -0.79 | -0.67 | -1.06 | -1.09 | -1.55 | -1.16 | -1.49 | -1.17 | -0.89 | -0.75 | -0.9 | -0.66 | -0.71 | -10.9 | -9 | -9.05 | -4.81 | -3.6 | -1.08 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.44 | -10.9 | -2.4 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Drug manufacturers industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cumberland Pharmaceuticals
CPIX
|
-0.14 | $ 4.37 | -3.96 % | $ 61.4 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-0.34 | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
-1.05 | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-0.18 | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.61 | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-6.71 | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-0.84 | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-15.8 | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-0.51 | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
-5.76 | - | - | $ 11.5 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-9.66 | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-0.89 | - | 2.45 % | $ 38.1 M |  Canada |
 |
Eagle Pharmaceuticals
EGRX
|
2.76 | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-10.4 | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-2.33 | - | - | $ 36.6 M | USA |
 |
Bausch Health Companies
BHC
|
-1.62 | $ 5.65 | 0.18 % | $ 2.06 B | Canada |
 |
Pacira BioSciences
PCRX
|
-2.15 | $ 23.69 | -4.44 % | $ 1.1 B | USA |
 |
Canopy Growth Corporation
CGC
|
-5.56 | $ 1.15 | 6.48 % | $ 124 M | Canada |
 |
Harrow Health
HROW
|
-0.14 | $ 40.27 | -0.57 % | $ 1.48 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-2.79 | $ 1.19 | -3.25 % | $ 1.48 M | USA |
 |
Solid Biosciences
SLDB
|
-1.99 | $ 7.2 | 4.35 % | $ 630 M | USA |
 |
Aurora Cannabis
ACB
|
-4.1 | $ 3.54 | 2.91 % | $ 86.3 M | Canada |
 |
Jupiter Wellness
JUPW
|
-17 | - | - | $ 33.6 M | USA |
 |
Tilray
TLRY
|
-2.35 | - | - | $ 3.56 B | Canada |
 |
Lannett Company
LCI
|
-5.74 | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
-0.477 | $ 1.39 | - | $ 402 M | Canada |
 |
Veru
VERU
|
-0.28 | $ 2.22 | 0.45 % | $ 299 M | USA |
 |
Evolus
EOLS
|
-0.8 | $ 6.32 | -0.78 % | $ 407 M | USA |
 |
Sundial Growers
SNDL
|
-1.1 | - | - | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
-14.8 | $ 9.1 | 0.55 % | $ 466 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-4.24 | - | - | $ 193 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-0.01 | $ 2.56 | -1.16 % | $ 337 M | USA |
 |
cbdMD
YCBD
|
-1.79 | $ 0.91 | 7.36 % | $ 3.92 M | USA |
 |
ProPhase Labs
PRPH
|
1.17 | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-1.49 | - | - | $ 1.42 B | USA |
 |
Assertio Holdings
ASRT
|
-4.74 | - | - | $ 142 M | USA |
 |
PetIQ
PETQ
|
0.07 | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-1.45 | - | - | $ 310 M | USA |
 |
Recro Pharma
REPH
|
-0.14 | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-0.32 | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-0.17 | $ 0.98 | 4.14 % | $ 48.9 M | USA |
 |
PLx Pharma
PLXP
|
-2.06 | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
0.05 | $ 15.95 | 2.8 % | $ 19.1 B | USA |
 |
Zomedica Corp.
ZOM
|
-0.08 | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-0.82 | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-0.15 | - | - | $ 29.1 M | USA |
 |
China Pharma Holdings
CPHI
|
-0.74 | - | - | $ 2.36 M |  China |
 |
TherapeuticsMD
TXMD
|
-0.05 | $ 2.03 | -1.93 % | $ 23.5 M | USA |